Kinetics of CAR-T cells and immunological profile after tisagenlecleucel therapy

This is the authors' abstract. We don't add key points for this paper.

Over the last decade, the use of chimeric antigen receptor (CAR) T cells has emerged a new strategy in treatment of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).The immune activation plays a pivotal role both in therapeutic effect of CAR-T cells and the side effects of the therapy.The most common toxicities related to CAR-T cell treatment, which are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), are caused by the excessive activation of effector cells and the release of high levels of cytokines [1,2].